Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2026 Half-Year Report (half-year ended 30 June 2026) Attachment 2026 Half-year Financial Report_Ipsen S.A. ...

H1 2026 results with sales growth of 23.5% at CER1, or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8%1 and core operating income of €845m, growing by 28.8% as...